Regeneron Pharmaceuticals Inc.

Pharmaceuticals
United States
Earnings Per Share Growth (%)79.80%
Cost of Goods Sold (US$ Millions)$393
Current Liabilities (US$ Millions)$811
Total Assets (US$ Millions)$2,915
Long Term Debt$363
Return on Equity25.02%
Revenue (US$ Millions)$4,104
Total Company Assets$5,609
Revenue Growth (%)45.55%
Net Income (US$ Millions)$636
Earnings Per Share (US$)$79.80
Total Equity (US$ Millions)$3,655
Profit Margin (%)15.50%
Debt To Equity Ratio (%)0.10%
Inventory Turnover$239